Hi NZT,
Looking back at Clinical Trials Update 24th May:
Further, PharmAust has signed an agreement to evaluate MPL in transgenic “humanised” mice, which
will express the receptors that the COVID-19 virus binds to in humans. Efficacy in this anti-viral model
will provide further evidence of the anti-viral effects of MPL.
It was not explicitly stated who the agreement was signed with. If it was with a potential partner then I can understand the identity being excluded. I am guessing this is all under the guidance of Ergomed.
Agree with you that we as shareholders need to have better messaging so that we don't have to try and guess the details.
- Forums
- ASX - By Stock
- PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
Hi NZT,Looking back at Clinical Trials Update 24th May:Further,...
-
-
- There are more pages in this discussion • 543 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.65M |
Open | High | Low | Value | Volume |
17.0¢ | 18.0¢ | 17.0¢ | $94.51K | 540.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 262452 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 40400 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 262452 | 0.170 |
11 | 205400 | 0.165 |
6 | 141500 | 0.160 |
4 | 512800 | 0.155 |
10 | 378999 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 40400 | 3 |
0.180 | 301726 | 5 |
0.185 | 184496 | 3 |
0.190 | 268528 | 5 |
0.195 | 233327 | 5 |
Last trade - 12.25pm 15/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online